Abstract
Background and aims
Type 1 gastric neuroendocrine tumour surveillance and treatment are a matter of debate.
Endoscopic, or surgical, resection and chronic somatostatin analog therapy have been
proposed. Based on the favourable behaviour of this neoplasm, we performed an endoscopic
and clinical follow-up in 11 patients affected by type 1 gastric neuroendocrine tumours,
avoiding any specific treatment.
Methods
Between 1994 and 2006, we prospectively recorded the data of 11 untreated patients
with type 1 gastric neuroendocrine tumours who underwent an endoscopic and clinical
follow-up. All the patients were also evaluated by means of an abdominal computed
tomography scan, somatostatin receptor scintigraphy and blood tests.
Results
During the follow-up (median 54 months, range 9–136), the endoscopic picture of 4
(36%) out of 11 patients changed in terms of increased number of lesions. In none
of the cases were detected any lesions that exceeded 10 mm in diameter, and none of the patients demonstrated any evidence of local or distant
metastases.
Conclusions
Our data confirm the literature data of the indolent behaviour of type 1 gastric neuroendocrine
tumours and suggest that a careful endoscopic follow-up, without any treatment, might
represent a reasonable and safe option in selected patients.
Abbreviations:
APCA (anti-parietal cell antibodies), CAG (chronic atrophic gastritis), CgA (chromogranin A), CT (computed tomography), ECL (enterochromaffin-like), EUS (endoscopic ultrasonography), Hb (haemoglobin), 5 HIAA (5-hydroxyindolacetic acid), SRS (somatostatin receptor scintigraphy)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?.Am J Gastroenterol. 2004; 99: 23-32
- Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathological study.Gastroenterology. 1993; 104: 994-1006
- Gastric carcinoids.Ital J Gastroentrol Hepatol. 1999; 31: S94-S97
- ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.Gastroenterology. 1999; 116: 532-542
- Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.World J Surg. 1996; 20: 168-172
- Benign gastric carcinoid tumor with hypergastrinemia followed up for 12 years.Gastric Cancer. 2000; 3: 161-164
- Endoscopic mucosal resection in the management of gastric carcinoids tumors.Endoscopy. 2003; 35: 203-206
- Endoscopic resection with a two-channel videoendoscope for gastric carcinoid tumors.Hepatogastroenterology. 2004; 51: 269-272
- Rapid regression of enterochromaffinelike cell gastric carcinoids in pernicious anemia after antrectomy.Gastroenterology. 1992; 102: 1409-1418
- Multiple gastric carcinoids associated with hypergastrinemia. A review of five cases with clinicopathological analysis and surgical strategies.Anticancer Res. 2005; 25: 4417-4422
- Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis.Gastric Cancer. 2005; 8: 42-46
- Multiple gastric carcinoids.J Am Coll Surg. 2003; 196: 984-985
- Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours.Neuroendocrinology. 2004; 80: 394-424
- Gastric carcinoid type I tumour: new diagnostic and therapeutic method.Eur J Gastroenterol Hepatol. 2003; 15: 705-707
- Treatment of ECL cell carcinoids with octyreotide LAR.Scand J Gastroenterol. 2004; 39: 621-628
- Endocrine tumours of the stomach.Best Pract Res Clin Gastroenterol. 2005; 19: 659-673
- Gastric carcinoid syndrome diagnosed by endoscopy.Am J Gastroenterol. 1981; 76: 41-43
- High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study.Am J Gastroenterol. 1999; 94: 766-772
- Gastric carcinoid tumors. The biology and therapy of an enigmatic and controversial lesion.Am J Gastroenterol. 1995; 90: 338-352
- Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid.Eur J Gastroenterol Hepatol. 2001; 13: 1449-1456
- Type 1 gastric carcinoid: is the conservative approach always indicated?.Endoscopy. 2004; 36: 457-465
- Carcinoid tumors of the stomach.Surg Oncol. 2003; 12: 153-172
- Computed tomography of abdominal carcinoid tumors.Am J Radiol. 1984; 143: 581-584
- Somatostatin receptor scintigraphy and radionuclide therapy.Digestion. 1996; 57: 57-61
- Carcinoid tumors of the gastrointestinal tract: evaluation with endoscopic ultrasonography.Gastrointest Endosc. 1993; 39: 375-383
Article info
Publication history
Accepted:
January 23,
2007
Received:
August 28,
2006
Identification
Copyright
© 2007 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Inc. All rights reserved.
